For research use only. Not for therapeutic Use.
Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC50 values of 64.6 nM and 197 nM for hmGlu4/Gqi5 and rmGlu4 GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson’s disease[1].
Valiglurax (VU0652957; 0.3-30 mg/kg; po) reverses haloperidol (HY-14538)-induced catalepsy (HIC) in rats in a dose-dependent manner[1].
| Catalog Number | I037942 |
| CAS Number | 1976050-09-5 |
| Synonyms | N-(2H-pyrazolo[3,4-b]pyridin-3-yl)-1-(trifluoromethyl)isoquinolin-6-amine |
| Molecular Formula | C16H10F3N5 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H10F3N5/c17-16(18,19)13-11-4-3-10(8-9(11)5-7-20-13)22-15-12-2-1-6-21-14(12)23-24-15/h1-8H,(H2,21,22,23,24) |
| InChIKey | RUEXKBWCUUFJMY-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(NN=C2N=C1)NC3=CC4=C(C=C3)C(=NC=C4)C(F)(F)F |
| Reference | [1]. Panarese JD, et, al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. |
